The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Jean-Jacques KiladjianDuring the European School of Haematology 4th How to Diagnose and Treat: CML/MPN conference, the MPN Hub hosted a symposium titled “Anemia in myelofibrosis: Sequencing therapies to optimize patient outcomes.”
Anemia in myelofibrosis: Q&A
The symposium closed with a panel Q&A session that included live audience participation. The panelists, Jean-Jacques Kiladjian, Francesco Passamonti, and Paola Guglielmelli, shared their perspectives on the optimal sequencing of therapies for patients with myelofibrosis-related anemia, the use of iron chelation therapy, potential future combination therapies, and the use of anemia supportive agents.
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
More from this series:
